Abstract

8548 Background: Previous data indicated that the overall survival (OS) of patients (pts) with AIDS-related Burkitt lymphoma (BL) is inferior to that of diffuse large B-cell lymphoma (DLBCL), and t...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy.
Umberto Tirelli ... Antonino Carbone
AIDS (London, England) | VOL. 14
Umberto Tirelli, et. al.Umberto Tirelli ... Antonino Carbone
01 Aug 2000
Newer monoclonal antibodies for hematological malignancies
Jorge Castillo ... Peter Quesenberry
Experimental hematology | VOL. 36
Jorge Castillo, et. al.Jorge Castillo ... Peter Quesenberry
17 Jun 2008
Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature
Anca Prica ... Rena Buckstein
Blood | VOL. 122
Anca Prica, et. al.Anca Prica ... Rena Buckstein
15 Nov 2013
Rituxiamb Did Not Improve Clinical Outcomes In AIDS-Related Burkitt Lymphoma
Hideyuki Yamamoto ... Hirokazu Nagai
Blood | VOL. 118
Hideyuki Yamamoto, et. al.Hideyuki Yamamoto ... Hirokazu Nagai
18 Nov 2011
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Influence of Nucleophosmin ( NPM1 ) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
Claudia Tregnago ... Martina Pigazzi
Journal of Clinical Oncology | VOL. -
Claudia Tregnago, et. al.Claudia Tregnago ... Martina Pigazzi
02 Dec 2024
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer
Lajos Pusztai ... Kevin M Kalinsky
Journal of Clinical Oncology | VOL. -
Lajos Pusztai, et. al.Lajos Pusztai ... Kevin M Kalinsky
02 Dec 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O 6 -Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
Thomas Walter ...
Journal of Clinical Oncology | VOL. -
Thomas Walter, et. al.Thomas Walter ...
25 Nov 2024
Using Cure Models for Trial Analysis and Design
Michael L Leblanc
Journal of Clinical Oncology | VOL. -
Michael L LeblancMichael L Leblanc
25 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.